Hologic to Unveil Groundbreaking AI Research at ECR 2024
Global Leader in Women’s Health to
The pioneer behind 3D mammography, Hologic will present new data that showcase how next-generation deep-learning solutions can assist with breast cancer detection and improve workflow for radiologists. Presented by esteemed breast imaging specialist and study author Dr.
“These data reveal how AI can help us correlate ROIs in a way that we have never seen before, which underscores that deep-learning technology can supplement our workflow as radiologists and help us provide better patient care,” said
In addition,
“Research and education are central tenets of Hologic’s innovation, to support radiologists in achieving better patient outcomes,” said Tanja Brycker, Vice President, Strategic Development,
Hologic and Bayer will co-sponsor a contrast-enhanced mammography (CEM) symposium, facilitated by globally recognized breast imaging radiologists Dr.
The symposium, which will take place on
Hologic’s Genius AI® Detection technology is a cutting-edge solution now commercially available in the
About
The company also champions women through the Hologic Global Women’s Health Index, which provides a science-backed data framework for improving women’s well-being.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to womenshealth@hologic.com.
Hologic, The Science of Sure and Genius AI are trademarks and/or registered trademarks of
Views and opinions expressed herein by third parties are theirs alone and do not necessarily reflect those of Hologic. Dr.
Source:
____________________ | ||
1 |
Correlating breast lesions in tomosynthesis CC and MLO views using artificial intelligence (AI).Authors: |
|
2 |
Evaluating performance of an artificial intelligence (AI) detection system on prior screening tomosynthesis studies of breast cancer patients. Authors: |
|
3 |
Performance of a traditional machine learning computer-aided detection ( |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227246191/en/
Media Contact
Director, Corporate Communications
+1 508.263.8654
bridget.perry@hologic.com
Investor Contact
Vice President, Investor Relations
+1 858.410.8514
ryan.simon@hologic.com
Source: